Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$131.67
+4.0%
$129.71
$99.71
$141.23
$228.35B0.75.45 million shs8.44 million shs
Citigroup Inc. stock logo
C
Citigroup
$71.90
-1.8%
$77.26
$53.51
$84.74
$135.32B1.4313.21 million shs13.15 million shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+4.12%+3.91%-3.21%+14.50%+16.04%
Citigroup Inc. stock logo
C
Citigroup
-1.79%+0.13%-8.00%+1.26%+14.58%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8631 of 5 stars
2.44.02.54.54.12.52.5
Citigroup Inc. stock logo
C
Citigroup
4.9866 of 5 stars
3.43.02.52.63.32.55.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.84
Moderate Buy$137.944.76% Upside
Citigroup Inc. stock logo
C
Citigroup
2.79
Moderate Buy$84.5017.53% Upside

Current Analyst Ratings Breakdown

Latest ABT and C Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2025
Citigroup Inc. stock logo
C
Citigroup
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $80.00
3/13/2025
Citigroup Inc. stock logo
C
Citigroup
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $109.00
3/10/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$133.00 ➝ $150.00
3/4/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$135.00 ➝ $160.00
3/4/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$138.00 ➝ $154.00
1/28/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
1/27/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$149.00 ➝ $158.00
1/23/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $135.00
1/23/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$133.00 ➝ $136.00
1/23/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$146.00 ➝ $148.00
1/21/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$135.00 ➝ $135.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.44$5.67 per share23.22$22.36 per share5.89
Citigroup Inc. stock logo
C
Citigroup
$81.09B1.67$7.77 per share9.25$101.26 per share0.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.6517.2122.982.5231.95%20.74%11.19%4/16/2025 (Estimated)
Citigroup Inc. stock logo
C
Citigroup
$12.68B$5.9512.087.610.647.43%6.62%0.53%4/15/2025 (Estimated)

Latest ABT and C Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2025N/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07N/AN/AN/A$10.38 billionN/A
4/15/2025N/A
Citigroup Inc. stock logo
C
Citigroup
$1.84N/AN/AN/A$21.34 billionN/A
1/22/2025Q4 2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.34$1.34N/A$5.27$11.03 billion$10.97 billion
1/15/2025Q4 24
Citigroup Inc. stock logo
C
Citigroup
$1.22$1.34+$0.12$1.34$19.51 billion$19.58 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.79%N/A30.85%N/A
Citigroup Inc. stock logo
C
Citigroup
$2.243.12%+2.24%37.65%N/A

Latest ABT and C Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.75%4/15/20254/15/20255/15/2025
1/14/2025
Citigroup Inc. stock logo
C
Citigroup
quarterly$0.563.04%2/3/20252/3/20252/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.14
Citigroup Inc. stock logo
C
Citigroup
1.50
0.96
0.96

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Citigroup Inc. stock logo
C
Citigroup
71.72%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Citigroup Inc. stock logo
C
Citigroup
0.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.73 billion1.73 billionOptionable
Citigroup Inc. stock logo
C
Citigroup
240,0001.88 billion1.89 billionOptionable

Recent News About These Companies

Citigroup Inc. (C) Files Current Report on Form 8-K
Norges Bank Unexpectedly Leaves Rate Unchanged Again
Citigroup hiring dealmakers in Japan with fee pool seen reviving
Leadership overhang, derivative issues prompt Emkay to exit IndusInd Bank

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$131.67 +5.06 (+3.99%)
Closing price 03/27/2025 03:59 PM Eastern
Extended Trading
$131.75 +0.08 (+0.06%)
As of 03/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Citigroup stock logo

Citigroup NYSE:C

$71.90 -1.34 (-1.84%)
Closing price 03/27/2025 03:59 PM Eastern
Extended Trading
$72.06 +0.16 (+0.22%)
As of 03/27/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citigroup Inc., a diversified financial service holding company, provides various financial product and services to consumers, corporations, governments, and institutions worldwide. It operates through five segments: Services, Markets, Banking, U.S. Personal Banking, and Wealth. The Services segment includes Treasury and Trade Solutions, which provides cash management, trade, and working capital solutions to multinational corporations, financial institutions, and public sector organizations; and Securities Services, such as cross-border support for clients, local market expertise, post-trade technologies, data solutions, and various securities services solutions. The Markets segment offers sales and trading services for equities, foreign exchange, rates, spread products, and commodities to corporate, institutional, and public sector clients; and market-making services, including asset classes, risk management solutions, financing, prime brokerage, research, securities clearing, and settlement. The banking segment includes investment banking; advisory services related to mergers and acquisitions, divestitures, restructurings, and corporate defense activities; and corporate lending, which includes corporate and commercial banking. The U.S. Personal Banking segment provides co-branded cards and retail banking services. The Wealth segment provides financial services to high-net-worth clients through banking, lending, mortgages, investment, custody, and trust product offerings; and to professional industries, including law firms, consulting groups, accounting, and asset management. The company was founded in 1812 and is headquartered in New York, New York.